6 unknown. 6 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Unknown 6 |
| Phase 1 | 1 | Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow SARS-CoV 2: new trials by email Literature Review of SARS-CoV 2 trials Research Report on SARS-CoV 2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory in Treating COVID-19 Disease Lactoferrin (Apolactoferrin), Placebo of excipient(s) will be administered - Corona Virus Infection, Middle East Respiratory Syndrome (MERS) | Phase 2 | Unknown | National Research Centre, Egypt | 516 | 2022-02-01 | 2021-11-15 |
| P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19 P2Et (Caesalpinia spinosa extract), Placebo - COVID, Coronavirus Infection | Phase 2 / Phase 3 | Unknown | Hospital Universitario San Ignacio | 100 | 2020-09-30 | 2021-08-10 |
| Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19 Masitinib, Isoquercetin, Best Supportive Care - SARS-CoV 2, COVID-19 | Phase 2 | Unknown | AB Science | 200 | 2020-06-01 | 2023-02-06 |
| Baricitinib Compared to Standard Therapy in Patients With COVID-19 Baricitinib Oral Tablet - Covid-19, SARS-CoV 2 | Phase 2 | Unknown | Azienda Ospedaliero, Universitaria Pisana | 126 | 2020-05-20 | 2020-05-20 |
| CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19 convalescent plasma - COVID-19, SARS-CoV 2 | Phase 1 / Phase 2 | Unknown | Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado | 90 | 2020-05-20 | 2020-06-05 |
| Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora Oxygen-ozone therapy, probiotic supplementation and Standard of care, SivoMixx (200 billion), Azithromycin - COVID, SARS-CoV 2 | Phase 2 | Unknown | Roberto Poscia MD, PhD | 152 | 2020-03-26 | 2020-04-28 |
COVID-19 (5) · Coronavirus Infections (3) · Convalescence (1) · Cytokine Release Syndrome (1) · Pneumonia (1) · Pneumonia, Viral (1) · Respiratory Distress Syndrome (1)
Coronaviridae Infections (6) · Infections (6) · Lung Diseases (6) · Nidovirales Infections (6) · RNA Virus Infections (6) · Respiratory Tract Diseases (6) · Respiratory Tract Infections (6) · Virus Diseases (6) · Pneumonia (5) · Pneumonia, Viral (5) · Coronavirus Infections (3) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Disease Attributes (1) · Inflammation (1)
Azithromycin (1) · Hydroxychloroquine (1) · Lactoferrin (1) · Standard of Care (1) · apolactoferrin (1) · baricitinib (1) · isoquercitrin (1) · masitinib (1)
AB Science (1) · Azienda Ospedaliero, Universitaria Pisana (1) · Hospital Universitario San Ignacio (1) · Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (1) · National Research Centre, Egypt (1) · Roberto Poscia MD, PhD (1)
Italy (2) · Colombia (1) · Egypt (1) · France (1) · Mexico (1)
Francesco Menichetti, MD (1) · Francesco Pugliese, MD, PhD (1) · Luis M Villela, MD (1) · Pascal Chanez, MD (1) · Rehab Hegazy, PhD (1)
PMID 11023960, PMID 20370679, PMID 25457751, PMID 32032529, PMID 32125452, PMID 32150360, PMID 32219428, PMID 32228825, PMID 32251638, PMID 32303365, PMID 36048877, PMID 36160152, PMID 37117213, PMID 3898484